Items where Author is "Abdelkader, H"
 | Up a level |
ABDELKADER, H., FATHALLA, Z., MOHARRAM, H., ALI, T.F.S. and PIERSCIONEK, B., 2018. Cyclodextrin enhances corneal tolerability and reduces ocular toxicity caused by diclofenac. Oxidative Medicine and Cellular Longevity, 2018: 5260976. ISSN 1942-0900
ABDELKADER, H., LONGMAN, M.R., ALANY, R.G. and PIERSCIONEK, B., 2016. Phytosome-hyaluronic acid systems for ocular delivery of L-carnosine. International Journal of Nanomedicine, 11, pp. 2815-2827. ISSN 1178-2013
ABDELKADER, H., LONGMAN, M., ALANY, R.G. and PIERSCIONEK, B., 2016. On the anticataractogenic effects of L-carnosine: is it best described as an antioxidant, metal-chelating agent or glycation inhibitor? Oxidative Medicine and Cellular Longevity, 2016, p. 3240261. ISSN 1942-0900
ABDELKADER, H., SWINDEN, J., PIERSCIONEK, B.K. and ALANY, R.G., 2015. Analytical and physicochemical characterisation of the senile cataract drug dipeptide β-alanyl-L-histidine (carnosine). Journal of Pharmaceutical and Biomedical Analysis, 114, pp. 241-246. ISSN 0731-7085
ABDELKADER, H., ALANY, R.G. and PIERSCIONEK, B., 2015. Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens. Journal of Pharmacy and Pharmacology, 67 (4), pp. 537-550. ISSN 0022-3573
RAI, U.D.J.P., YOUNG, S.A., THRIMAWITHANA, T.R., ABDELKADER, H., ALANI, A.W.G., PIERSCIONEK, B. and ALANY, R.G., 2015. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discovery Today, 20 (4), pp. 491-495. ISSN 1359-6446
ABDELKADER, H., PIERSCIONEK, B., CAREW, M., WU, Z. and ALANY, R.G., 2015. Critical appraisal of alternative irritation models: three decades of testing ophthalmic pharmaceuticals. British Medical Bulletin, 113 (1), pp. 59-71. ISSN 0007-1420
ABDELKADER, H., PIERSCIONEK, B. and ALANY, R.G., 2014. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. International Journal of Pharmaceutics, 477 (1-2), pp. 631-642. ISSN 0378-5173
